Adverse events related to antimuscarinics and beta-3-agonist: "real-life" data from the Eudra-Vigilance Database

Nunzio, Cosimo De; Nacchia, Antonio; Gravina, Carmen; Turchi, Beatrice; Gallo, Giacomo; Trucchi, Alberto; Giacomo, Ferdinando Di; Disabato, G; Franco, Antonio; Rovesti, Lorenzo Maria; Lombardo, Riccardo; Cicione, Antonio; Tubaro, Andrea

doi:10.23736/s2724-6051.22.04849-2

Cited by 7 publications

(3 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The major antibiotics (aminoglycosides and fluoroquinolones) used for treatment of bacterial keratitis were approved in the 1970s through the early 2000s. Fluoroquinolone and aminoglycoside class antibiotics have concerning side effects and increasing rates of bacterial resistance leading to reduced use for systemic infections [12][13][14] . The more recent ocular antibiotics, such as moxifloxacin and besifloxacin, were designed for better efficacy against Gram-positive bacteria.…”

Section: Introductionmentioning

confidence: 99%

Cefiderocol is an effective topical monotherapy for experimental extensively-drug resistantPseudomonas aeruginosakeratitis

Romanowski,

Mumper,

Shanks

et al. 2023

Preprint

View full text Add to dashboard Cite

Purpose: To test cefiderocol, a siderophore-cephalosporin antibiotic for topical monotherapy treatment of experimental extensively drug resistant (XDR) Pseudomonas aeruginosa keratitis. Design: Preclinical study. Subjects and Controls: Deidentified P. aeruginosa keratitis isolates, XDR P. aeruginosa from eye drop outbreak, rabbits, saline, cefiderocol 50 mg/ml, ciprofloxacin 0.3%, and tobramycin 14 mg/ml. Methods, Intervention, or Testing: Cefiderocol antibacterial activity against P. aeruginosa keratitis isolates (n=135) was evaluated by minimum inhibitory concentration (MIC) testing. Ocular toxicity/tolerability and antibacterial efficacy were tested in vivo with experimental rabbit models. Main Outcome Measures: MIC analysis for susceptibility, graded tests for ocular toxicity/tolerability, CFU analysis for bacterial burden, corneal cefiderocol concentrations. Results: 100% of P. aeruginosa keratitis isolates were susceptible to cefiderocol (n=135), the MIC90 was 0.125 ug/ml including the XDR isolate (MIC = 0.125 ug/ml). Topical cefiderocol 50 mg/ml was minimally toxic to the ocular surface and was well tolerated. For the XDR P. aeruginosa isolate, topical cefiderocol 50 mg/ml, significantly decreased corneal CFU compared to ciprofloxacin 0.3%, tobramycin 14 mg/ml, and saline. In addition, tobramycin 14 mg/ml was more effective than the saline control. Mean cefiderocol corneal concentrations were 191x greater than the MIC90 of the P. aeruginosa keratitis isolates. Conclusions: These results demonstrate that cefiderocol is well tolerated on rabbit corneas and is effective against P. aeruginosa keratitis isolates in vitro and was effective in vivo against an XDR isolate. Given the recent outbreak of keratitis caused by this XDR P. aeruginosa, cefiderocol is a promising additional antibiotic that should be further evaluated for topical treatment of keratitis caused by antibiotic resistant P. aeruginosa.

show abstract

Section: Introductionmentioning

confidence: 99%

Cefiderocol is an effective topical monotherapy for experimental extensively-drug resistantPseudomonas aeruginosakeratitis

Romanowski,

Mumper,

Shanks

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

“…Blayne Welk et al found that antimuscarinics may increase the risk of mortality, and a single multicenter study showed that the mortality of β3 agonist users was 20% lower than that of antimuscarinics users (8). Mirabegron and vibegron, β3 receptor agonists, significantly improved the daily number of urgency episodes and micturition without anticholinergic adverse effects (7,9,10). Recently, more attention has been given to the combination treatment of antimuscarinics plus mirabegron (11,12).…”

Section: Introductionmentioning

confidence: 99%

Comparison of different types of therapy for overactive bladder: A systematic review and network meta-analysis

Liu

Shi

et al. 2022

Front. Med.

View full text Add to dashboard Cite

To compare the efficacy and safety of different interventions [including antimuscarinics, mirabegron, OnabotulinumtoxinA, sacral neuromodulation (SNM) and peripheral tibial nerve stimulation (PTNS)] for treating idiopathic overactive bladder (OAB). PubMed, Embase, Cochrane Library, and other sources were searched for randomized controlled trials (RCTs) comparing interventions for overactive bladder from 1 January 2000 to 19 April 2021. A systematic review and network meta-analysis were performed by two authors independently. Fifty-five RCTs involving 32,507 patients were included in this analysis. Overall, antimuscarinics, mirabegron, OnabotulinumtoxinA, sacral neuromodulation, and peripheral tibial nerve stimulation were more efficacious than placebo, and sacral neuromodulation showed the best effect for reducing micturition frequency, urgency episodes and urgency urinary incontinence episodes. OnabotulinumtoxinA was the best intervention for achieving reductions of 100 and ≥50% in the number of urinary incontinence episodes/day, and peripheral tibial nerve stimulation was the best intervention for reducing urinary incontinence episodes. Antimuscarinics, mirabegron and peripheral tibial nerve stimulation had a similar efficacy for reducing micturition frequency, urinary incontinence episodes and urgency urinary incontinence episodes. The results revealed that all interventions examined herein were efficacious for managing adult overactive bladder syndrome compared with placebo. Furthermore, sacral neuromodulation and OnabotulinumtoxinA were the most efficient treatments for overactive bladder.Systematic review registration[https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=251966], identifier [CRD42021251966].

show abstract

“…Anticholinergic and β-3 agonist therapy are the standard first-line pharmacological treatments for treating patients with OAB, but both have many corresponding side effects. For example, anticholinergic side effects include dry mouth, blurred vision, and constipation; β-3 agonist, while having a lower incidence of anticholinergic side effects, exhibit a higher risk of hypertension [ 11 ]. Therefore, it is urgent to find a convenient, more effective and less side effect treatment.…”

Section: Introductionmentioning

confidence: 99%

Mechanism of traditional Chinese medicine in treating overactive bladder

Liao

et al. 2022

Int Urol Nephrol

View full text Add to dashboard Cite

Overactive bladder syndrome (OAB) has made increasing progress in mechanism and treatment research. Traditional Chinese medicine (TCM) is a common complementary therapy for OAB, and it has been found to be effective. However, the intervention mechanism of TCM in the treatment of OAB is still unclear. The aim of this review is to consolidate the current knowledge about the mechanism of TCM: acupuncture, moxibustion, herbs in treating OAB, and the animal models of OAB commonly used in TCM. Finally, we put forward the dilemma of TCM treatment of OAB and discussed the insufficiency and future direction of TCM treatment of OAB.

show abstract

Adverse events related to antimuscarinics and beta-3-agonist: "real-life" data from the Eudra-Vigilance Database

Cited by 7 publications

References 40 publications

Cefiderocol is an effective topical monotherapy for experimental extensively-drug resistantPseudomonas aeruginosakeratitis

Cefiderocol is an effective topical monotherapy for experimental extensively-drug resistantPseudomonas aeruginosakeratitis

Comparison of different types of therapy for overactive bladder: A systematic review and network meta-analysis

Mechanism of traditional Chinese medicine in treating overactive bladder

Contact Info

Product

Resources

About